Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InSilico Medicine Cayman TopCo (OTCPK:ISLMF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
InSilico Medicine Cayman TopCo Net Cash per Share Related Terms
InSilico Medicine Cayman TopCo Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo Net Cash per Share Chart
For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InSilico Medicine Cayman TopCo Price-to-Net-Cash vs Software Industry
For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where InSilico Medicine Cayman TopCo's Price-to-Net-Cash falls into.
InSilico Medicine Cayman TopCo Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo (ISLMF) has a Net Cash per Share of $0.73 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on InSilico Medicine Cayman TopCo and its competitors. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #420 out of 841 companies in the Software industry, placing it in the top 49.9%.
Is InSilico Medicine Cayman TopCo's Net Cash per Share too high?
InSilico Medicine Cayman TopCo's current Net Cash per Share is $0.73. The Software industry median Net Cash per Share is 8.17. InSilico Medicine Cayman TopCo's value of $0.73 is 91.1% below this industry median. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #420 out of 841 companies in the Software industry, which is above the industry midpoint. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's Net Cash per Share compare to ?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #420 out of 841 companies for Net Cash per Share. This puts InSilico Medicine Cayman TopCo in the upper half of its industry. The industry median Net Cash per Share is 8.17. InSilico Medicine Cayman TopCo's value of $0.73 is 91.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Software company?
The median Net Cash per Share among Software companies is 8.17, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InSilico Medicine Cayman TopCo's current Net Cash per Share of $0.73 is 91.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on InSilico Medicine Cayman TopCo and its competitors. For the Software industry, the median Net Cash per Share is 8.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current Net Cash per Share is $0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (ISLMF) has a current Net Cash per Share of $0.73. The current Net Cash per Share is $0.73 and 91.1% below the Software industry median of 8.17. InSilico Medicine Cayman TopCo's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (ISLMF), the current Net Cash per Share is $0.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
13GF Score
Get the complete analysis for ISLMF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISLMF has been successfully added to your 
